The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease
Abstract
Objective To evaluate the efficacy and tolerability of lubiprostone (Amitiza) for constipation in Parkinson disease (PD) in a double-blind, randomized, controlled study. Methods Patients with PD and clinically meaningful constipation (constipation rating scale score > 10 [range: 0-28]) were recruited from 2 academic movement disorder centers to participate in the study. After enrollment, patients were initially followed for 2 weeks and then were randomly assigned 1:1 to lubiprostone, and the dose was titrated up to 48 μg/day. They returned 4 weeks later for a final assessment. Data included stool diaries and global impressions (co-primary endpoints), demographics, Unified Parkinson's Disease Rating Scale scores, constipation scale scores, visual analog scale (VAS) scores, a stool diary, and adverse events. Results Fifty-four subjects (39 male, mean age 67.0 ± 10.1 years, and mean duration of PD 8.3 ± 5.4 years) were randomly assigned to lubiprostone or placebo. One patient in the drug group discontinued the study because of logistics, and one patient in the placebo group discontinued the study because of lack of efficacy. A marked or very marked clinical global improvement was reported by 16 of 25 (64.0%) subjects receiving drug vs 5 of 27 (18.5%) subjects receiving placebo (p = 0.001). The constipation rating scale (p Conclusion In this randomized controlled trial, lubiprostone seemed to be well tolerated and effective for the short-term treatment of constipation in PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trials have demonstrated benefit of polyethylene glycol 3350 (Zangaglia et al., 2007) and lubiprostone (Ondo et al., 2012) in PD-related constipation, and dopaminergic agents such as apomorphine can influence defecatory function (Edwards et al., 1993b).”
From Autonomic nervous system and gastrointestinal manifestations with an emphasis on gastric dysfunction (2026) · cites this paper as Ondo et al., 2012
Citations
Cites
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Frequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Martínez‐Martín, P., Schapira, A. H. V., Stocchi, F., Sethi, K. D., Odin, P., Macphee, G. J. A., Brown, R. G., Naidu, Y., Clayton, L. M. S., Abe, K., et al. (2007) · Movement Disorders · doi:10.1002/mds.21586 · Cited by 556
Self-citationLoss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease
Halliday, G. M., Blumbergs, P. C., Cotton, R. G. H., Blessing, W. W., & Geffen, L. B. (1990) · Brain Research · doi:10.1016/0006-8993(90)90733-r · Cited by 379
Gastrointestinal symptoms in Parkinson's disease
Edwards, L. L., Pfeiffer, R. F., Quigley, E. M. M., Hofman, R., & Balluff, M. (1991) · Movement Disorders · doi:10.1002/mds.870060211 · Cited by 373
Singaram, C., Gaumnitz, E., Torbey, C., Ashraf, W., Quigley, E. M., Sengupta, A., & Pfeiffer, R. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92707-7 · Cited by 364
Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease
Sakakibara, R., Shinotoh, H., Uchiyama, T., Sakuma, M., Kashiwado, M., Yoshiyama, M., & Hattori, T. (2001) · Autonomic Neuroscience · doi:10.1016/s1566-0702(01)00295-8 · Cited by 348
Cited by
Sorted by citations
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Chaudhuri, К. R., Coelho, M. M., Fox, S. H., Katzenschlager, R., Perez‐Lloret, S., Weintraub, D. A., & Sampaio, C. (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,013
Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT
Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S. A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003127 · Cited by 390
Chen, Z., Li, G., & Liu, J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 364
New evidence on the management of Lewy body dementia
Taylor, J.-P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., Allan, L. M., Thomas, A. J., & O'Brien, J. T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30153-x · Cited by 347
Metadata
- Authors
- Ondo, W. G., Kenney, C., Sullivan, K., Davidson, A., Hunter, C., Jahan, I., McCombs, A., Miller, A., & Zesiewicz, T. A.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- Neurology
- Published
- 2012-05-22
- Volume
- 78
- Issue
- 21
- Pages
- 1650-1654
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2041741770
- Cited by
- 112
- References
- 34
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 8 · 2020: 11 · 2019: 12 · 2018: 4 · 2017: 4 · 2016: 12 · 2015: 8 · 2014: 3 · 2013: 9 · 2012: 2
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Keywords
- lubiprostone, Parkinson's disease, constipation, gastrointestinal motility, prokinetic agents, drug efficacy, drug tolerability, stool frequency, adverse events
- MeSH terms
- Lubiprostone, Aged, Alprostadil, Constipation, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease, Placebos, Severity of Illness Index, Vasodilator Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
